Sign up
Pharma Capital

Genedrive partners with FIND to evaluate Hepatitis C diagnostic kit in Cameroon and Georgia

Under the agreement, FIND will lead evaluation studies between September 2018 and May 2019 to confirm the accuracy of Genedrive’s HCV kit across diverse genotypes
Hepatitis C
The studies will also evaluate the kit's usability in its intended markets

Genedrive PLC (LON:GDR) has partnered with the Foundation for Innovation of New Diagnostics (FIND) in a study agreement to evaluate its hepatitis C virus (HCV) identification kit.

The AIM-listed biotechnology firm said under the agreement, FIND would lead evaluation studies in Cameroon and Georgia between September 2018 and May 2019 to confirm the accuracy of Genedrive’s HCV kit across diverse genotypes, as well as its usability in the intended market of low-resource areas.

READ: Genedrive shares push higher as the rapid diagnostics specialist gears up for important year

The company added that FIND’s evaluations would feed into the organisation’s broader efforts as part of a multi-year, multi-country HCV project funded by Unitaid to support the development of simple HCV diagnostic tools for use at the point of care.

David Budd, Genedrive’s chief executive, said positive outcomes of the study would facilitate the company’s commercialisation activities in the relevant regions, while also “providing important clinical field data that others look to as they decide to implement [the Genedrive diagnostics platform] in their own specific settings."

View full GDR profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.